Patents by Inventor Harvey Brandwein

Harvey Brandwein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9931378
    Abstract: A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: April 3, 2018
    Assignee: IRX Therapeutics, Inc.
    Inventors: James E. Egan, Martin Kast, Harvey Brandwein
  • Publication number: 20160303198
    Abstract: A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.
    Type: Application
    Filed: April 13, 2016
    Publication date: October 20, 2016
    Applicant: IRX Therapeutics, Inc.
    Inventors: James E. Egan, Martin Kast, Harvey Brandwein
  • Patent number: 9333238
    Abstract: A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: May 10, 2016
    Assignee: IRX Therapeutics, Inc.
    Inventors: James E. Egan, Martin Kast, Harvey Brandwein
  • Patent number: 8591956
    Abstract: A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor escape.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: November 26, 2013
    Assignee: IRX Therapeutics, Inc.
    Inventors: John W. Hadden, Theresa L. Whiteside-Nimick, James E. Egan, Kathy L. Signorelli-Petrat, Harvey Brandwein
  • Publication number: 20120244117
    Abstract: A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.
    Type: Application
    Filed: December 8, 2010
    Publication date: September 27, 2012
    Applicant: IRX Therapeutics, Inc
    Inventors: James E. Egan, Martin Kast, Diane Da Silva, Harvey Brandwein
  • Publication number: 20120141512
    Abstract: A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor escape.
    Type: Application
    Filed: August 8, 2011
    Publication date: June 7, 2012
    Inventors: John W. Hadden, Theresa L. Whiteside, Margareta Czytowska, James E. Egan, Kathy L. Signorelli, Harvey Brandwein
  • Patent number: 7993660
    Abstract: A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor escape.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: August 9, 2011
    Assignee: IRx Therapeutics, Inc.
    Inventors: John W. Hadden, Theresa L. Whiteside, Margareta Czystowska, James E. Egan, Kathy L. Signorelli, Harvey Brandwein
  • Publication number: 20090155291
    Abstract: A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor escape.
    Type: Application
    Filed: November 26, 2008
    Publication date: June 18, 2009
    Inventors: John W. Hadden, Theresa L. Whiteside, Margareta Czystowska, James E. Egan, Kathy L. Signorelli, Harvey Brandwein
  • Publication number: 20030134417
    Abstract: The present invention provides methods of harvesting rare cells from blood products and/or obtaining products of the rare cells. The method includes contacting a blood product containing rare cells with a porous medium, and selectively retaining rare cells of interest on the porous medium. The porous medium can be contacted with an elution fluid wherein a population of the rare cells is eluted from the porous medium. Rare cells selectively retained on the porous medium can be cultured on the porous medium, and products of the rare cells can be obtained.
    Type: Application
    Filed: February 11, 2003
    Publication date: July 17, 2003
    Applicant: Pall Corporation
    Inventors: Harvey Brandwein, Samuel O. Coker
  • Patent number: 6544751
    Abstract: The present invention provides methods of harvesting rare cells from blood products and/or obtaining products of the rare cells. The method includes contacting a blood product containing rare cells with a porous medium, and selectively retaining rare cells of interest on the porous medium. The porous medium can be contacted with an elution fluid wherein a population of the rare cells is eluted from the porous medium. Rare cells selectively retained on the porous medium can be cultured on the porous medium, and products of the rare cells can be obtained.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: April 8, 2003
    Assignee: Pall Corporation
    Inventors: Harvey Brandwein, Samuel Coker
  • Patent number: 5266219
    Abstract: A device for separating plasma from blood is provided comprising a synthetic polymeric fibrous structure having a CWST in excess of 65 dynes/cm, the structure having a first region for receiving a blood sample and a second region for accumulating plasma.
    Type: Grant
    Filed: August 15, 1991
    Date of Patent: November 30, 1993
    Assignee: Pall Corporation
    Inventors: David B. Pall, Thomas C. Gsell, Vlado I. Matkovich, Harvey Brandwein
  • Patent number: 4606855
    Abstract: A method of determining the concentration of an antigen in a sample solution comprising(a) coating an antigen-protein conjugate onto a solid matrix,(b) conjugating an enzyme to an antibody specific for said antigen,(c) to a known quantity of a solution containing the antibody-enzyme conjugate of (b) adding a specified quantity of a sample containing an unknown amount of the antigen whose content is to be determined,(d) contacting the coated solid matrix of (a) with the solution (c) and incubate so as to effect binding between the antibody and antigen, some of the antigen being that from the sample and some being that on the solid matrix,(e) removing the solid matrix from the solution and washing,(f) immersing the solid matrix in a solution containing a known amount of an enzyme-substrate which is acted upon by the enzyme so as to effect reaction between the enzyme and enzyme-substrate to produce a product, and then separating the solid matrix form the solution of enzyme-substrate, and(g) then measuring the so
    Type: Grant
    Filed: July 22, 1983
    Date of Patent: August 19, 1986
    Assignee: Mex Research Associates c/o Leon Reimer
    Inventors: Alice Deutsch, Harvey Brandwein, Herbert Platt, Dianne M. Hunter, Andrew Dubitsky, Susan M. Durham
  • Patent number: 4477576
    Abstract: A method of determining the concentration of an antigen in a sample solution comprising(a) coating an antigen-protein conjugate onto a solid matrix,(b) conjugating an enzyme to an antibody specific for said antigen,(c) to a known quantity of a solution containing the antibody-enzyme conjugate of (b) adding a specified quantity of a sample containing an unknown amount of the antigen whose content is to be determined,(d) contacting the coated solid matrix of (a) with the solution (c) and incubate so as to effect binding between the antibody and antigen, some of the antigen being that from the sample and some being that on the solid matrix,(e) removing the solid matrix from the solution and washing,(f) immersing the solid matrix in a solution containing a known amount of an enzyme-substrate which is acted upon by the enzyme so as to effect reaction between the enzyme and enzyme-substrate to produce a product, and then separating the solid matrix from the solution of enzyme-substrate, and(g) then measuring the so
    Type: Grant
    Filed: July 26, 1982
    Date of Patent: October 16, 1984
    Assignee: Mex Research Associates
    Inventors: Alice Deutsch, Harvey Brandwein, Herbert Platt, Dianne M. Hunter, Andrew Dubitsky, Susan M. Durham